Skip to Content

Lawrence Halperin, MD

Telephone: 
(954) 776-6880
Fax: 
(954) 776-3393
Specialty/Specialties: 
Ophthalmology
No

Office hours
8am - 5pm, M-F

Languages
Spanish, Russian

Current leadership positions
Chairman, Federal Affairs Committee, American Society of Retina Specialists

Focus areas
Macular degeneration, diabetic retinopathy, macular pucker and hole, retinal detachment, retinal vein occlusion

Residency
Ophthalmology, Washington University School of Medicine

Fellowship
Retina and vitreous diseases, Washington University School of Medicine and Barnes Retina Institute

Certification
American Board of Ophthalmology

Professional Associations
American Academy of Ophthalmology
Association for Research in Vision and Ophthalmology
American Society of Retina Specialists
Broward County Ophthalmology Society
Palm Beach County Ophthalmology Society

Awards
Honored by Israel Bonds

Research
Principal Investigator, 1999-2003. A Phase III Randomized, Multi-centered, Doublemasked,
Placebo-controlled of Tin Ethyl Etiopurpurin (SNET2)
Photodynamic Therapy in Subfoveal Choroidal Neovascularization
Associated with Age Related Macular Degeneration. Miravant/Pharmacia


Principal Investigator, 2001-2003. Protocol B7A-MC-MBCM. Protein Kinase C
Inhibitor - Diabetic Retinopathy Study 2 (PKC-DRS2). A Phase 3 Clinical
Trial. Eli Lilly.


Principal Investigator, 2001-2003. A Randomized, Placebo-Controlled, Double-
Masked, Multi-centered, Phase II Study of Adjunctive diclofenac therapy
after Visudyne PDT in classic subfoveal CNV due to Age-Related Macular
Degeneration (Add-V). Novartis.


Principal Investigator, 2002-2005. A Randomized, Placebo-Controlled, Double-
Masked, Multi-centered Phase III Study of Visudyne Therapy in Occult
Subfoveal Choroidal Neovascularization (CNV) from Age-Related
Macular Degeneration (AMD) (VIO). QLT.


Principal Investigator, 2004-2005. Open-label study of Visudyne Therapy in occult
with no classic subfoveal choroidal neovascularization secondary to agerelated
macular degeneration. QLT (VIO OLD)


Principal Investigator, 2003-2006. A Phase III, Multi-centered, Randomized,
Double-Masked, Sham Injection-Controlled Study of the Efficacy and
Safety of rhuFab V2 in Subjects with Classic Subfoveal Neovascular Age-
Related Macular Degeneration (ANCHOR). Genentech.


Principal Investigator, 2003-2006. A Phase IIIb Randomized, Double-Masked,
Active Controlled, Multi-Center Trial Comparing the Safety and Efficacy
of Intravitreal Macugen (Anti-VEGF Pegylated Aptamer) to Visudyne
Photodynamic Therapy (PDT) in Classic Subfoveal Choroidal
Neovascularization, from Age-Related Macular Degeneration. Eyetech.


Principal Investigator, 2004 – ongoing. A Six-Month, Phase 3, Multicenter, Masked,
Randomized, Sham-Controlled Trial (with Six-Month Open-Label
Extension) to Assess the Safety and Efficacy of 700 ug and 350 ug
Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS)
Applicator System in the Treatment of Patients with Macular Edema
Following Central Retinal Vein Occlusion or Branch Retinal Vein
Occlusion. Allergan Pharmaceuticals 206207-009-00.


Principal Investigator, 2004-2006. A randomized, double-masked, sham controlled,
multicenter, phase II study comparing the safety and efficacy of
photodynamic therapy with Visudyne alone and administered in
conjunction with intravitreal triamcinolone acetonide in patients with
subfoveal choroidal neovascularization secondary to age-related macular
degeneration. Novartis (VisIT)


Principal Investigator, 2004-2006. An evaluation of efficacy and safety of
Anecortave Acetate 15 mg for depot suspension combined with
photodynamic therapy with Visudyne versus Anecortave Acetate
combined with sham PDT in patients with subfoveal exudative age-related
macular degeneration. Alcon Pharmaceuticals.


Principal Investigator, 2004-2006. A phase II randomized, double-masked, multicenter
trial, in parallel groups, to determine the safety, efficacy and
pharmacokinetics of intravitreal injections of pegaptanib sodium
compared to sham injection for 30 weeks in patients with recent vision
loss due to macular edema secondary to CRVO. Eyetech EOP1011.


Principal Investigator, 2004-2006. An open label, non-comparative protocol for the
use of pegaptanib sodium injection every 6 weeks in patients with
exudative age-related macular degeneration. Eyetech EPO1010.


Principal Investigator, 2004-2008. Multi-centered randomized phase II/III clinical
trial to study the effects of preservative-free triamcinolone acetate as an
adjunct to photodynamic therapy in participants with neovascular agerelated
macular degeneration. Sponsored by the National Eye Institute.


Principal Investigator, 2004-ongoing. 3-year phase III multi-centered masked
randomized sham controlled trial to assess the safety and efficacy of 700
ug and 350 ug dexamethasone posterior segment drug delivery system
(DEX PS DDS) applicator system in the treatment of patients with
diabetic macular edema. Allergan #206207-010-00


Principal Investigator, 2004-2006. Open label study of Visudyne therapy in occult
with no classic subfoveal choroidal neovascularization secondary to agerelated
macular degeneration (VIO OLS). QLT OCR 013025.


Principal Investigator, 2004-2006. Phase I/II randomized masked placebo controlled
single and multiple dose sequential dose escalation study of safety and
efficacy of AG-013958 in subjects with subfoveal choroidal
neovascularization associated with age-related macular degeneration.
Pfizer A4321001.


Principal Investigator, 2004-2009. An evaluation of the efficacy and safety of
posterior juxtascleral administration of Anecortave Acetate for depot
suspension vs. sham administration in patients at risk for developing sight
threatening choroidal neovascularization due to age-related macular
degeneration (AART). Alcon C-02-60.


Principal Investigator, 2005-2007. Phase IIIb, single-masked, multicenter,
randomized study to evaluate the safety and tolerability of ranibizumab
(Lucentis) in naïve and previously treated subjects with choroidal
neovascularization (CNV) secondary to Age-related Macular
Degeneration. Genentech FVF3689g. SAILOR


Principal Investigator, 2005-2007. A Phase II pharmacokinetic, randomized, doublemasked,
controlled, dose comparison study of Cand5 for intravitreal
injection for the treatment of diabetic macular edema. Acuity
Pharmaceuticals ACU211. Cand5 for DME.


Principal Investigator, 2005-ongoing. A randomized, double-masked, parallel group,
multi-center, dose-finding comparison of the safety and efficacy of
ASI-001A 0.5 ug/day and ASI-001B 0.2 ug/day fluocinolone acetonide
intravitreal inserts to sham injection in subjects with diabetic macular
edema. Alimera Sciences FAME C-01-05-001.


Principal Investigator, 2006-ongoing. Age Related Eye Disease Study II (AREDSII):
Multicenter, randomized trial of lutein, zeaxanthin, and long chain omega
3 fatty acids (docosahesanoic acid DHA and eicosapentanoic acid EPA) in
age-related macular degeneration. National Eye Institute.


Principal Investigator, 2006-2008. A Phase IV, open label, multi-center, study of
maintenance intravitreous Macugen injection every 6 weeks for 48 weeks
in patients with exudative subfoveal neovascular Age-Related Macular
Degeneration initially treated with a different modality resulting in
induced drying of the macula. Eyetech


Principal Investigator, 2006-2007. A phase 2/3 randomized, controlled, doublemasked,
multi-center, comparative dose-finding trial, in parallel groups, to
compare the safety and efficacy of intravitreous injections of 0.3, 0.03,
0.003 mg Macugen, given as often as every 6 weeks for 3 years, to sham
injections, in subjects with diabetic macular edema involving the center of
the macula. Eyetech/Pfizer EOP1013.


Principal Investigator, 2006-2007. Validation of the visual function questionnaire-25
(VFQ-25) in people with AMD. Genentech A2-3787.


Principal Investigator, 2006-ongoing. A Phase II/III study of encapsulated human
NTC-201 cell implants releasing ciliary neurotrophic factor (CNTF) for
participants with retinitis pigmentosa using visual field as the primary
outcome. Neurotech CNTF4.


Principal Investigator, 2006-ongoing. A Phase II/III study of encapsulated human
NTC-201 cell implants releasing ciliary neurotrophic factor (CNTF) for
participants with retinitis pigmentosa using visual acuity as the primary
outcome. Neurotech CNTF3.


Principal Investigator, 2006-ongoing. A phase II study of implants of encapsulated
human NTC-201 cell implants releasing ciliary neurotrophic factor
(CNTF), in participants with visual acuity impairment associated with
atrophic macular degeneration. Neurotech CNTF2.


Principal Investigator, 2006-ongoing. A randomized, controlled study of the safety,
tolerability and biological effect of repeated intravitreal administration of
VEGF trap in patients with neovascular age-related macular degeneration.
Regeneron, CLEAR-IT AMD-2, VGFT-OD-0508.

Principal Investigator, 2006-ongoing. A 24-month randomized, double-masked,
controlled, multi-center, phase IIIB study assessing safety and efficacy of
verteporfin (Visudyne) photodynamic therapy administered in conjunction
with ranibizumab (Lucentis) versus ranibisumab (Lucentis) monotherapy
in patients with subfoveal choroidal neovascularization secondary to agerelated
macular degeneration. Novartis CBPD962A2308.

Principal Investigator, 2005-2007. A phase IV, open-label, multicenter trial of
maintenance intravitreous injections of Macugen (pegaptanib) given every
6 weeks for 48 weeks in subjects with subfoveal neovascular age-related
macular degeneration initially treated with a different modality resulting in
maculopathy improvement. OSI Eyetech, EOP1023.

Principal Investigator, 2006-present. A 2-year, multicenter, randomized, controlled,
masked, dose-finding trial to assess the safety and efficacy of multiple
intravitreal injections of AGN 211745 (RNA-interference) in patients with
subfoveal choroidal neovascularization secondary to age-related macular
degeneration. Allergan, SIRIUS.

Principal Investigator, 2006-2007. Multi-center, randomized, phase II clinical trial to
study the effects of preservative-free triamcinolone acetonide and avastin
(bevacizumab) in combination with photodynamic therapy in participants
with neovascular age-related macular degeneration. National Eye
Institute, 05-EI-0064, VERTACL.

Principal Investigator, 2007-2009. The natural history of geographic atrophy
progression. This is a prospective natural history study in subjects with
geographic atrophy without choroidal neovascularization secondary to
age-related macular degeneration. GAP, Alcon Research, Ltd. C-06-30.

Principal Investigator, 2007-ongoing. A phase II study evaluating the subretinal
administration of CNTO 2476 in retinitis pigmentosa. Centocor/
Johnson&Johnson Internal Ventures.

Principal Investigator, 2007-ongoing. CNV Secondary to amd treated with beta
radiation epiretinal therapy. A randomized, prospective, active controlled,
study of the NeoVista system for the treatment of subfoveal choroidal
neovascularization associated with wet age-related macular degeneration.
NeoVista, Inc. CABERNET. NVI-114-01

Principal Investigator, 2008-ongoing. Monitoring for ophthalmic complications of a
new thrombin inhibitor. Schering Plough.

Principal Investigator, 2008-ongoing. A phase II multicenter, randomized, doublemasked,
placebo-controlled, dose-comparison study of the safety and
efficacy of fenretinide in the treatment of geographic atrophy in subjects
with age-related macular degeneration. SRFR-001. Sirion Therapeutics,
Inc.

Principal Investigator, 2007-ongoing. A 6-month, single-masked, multicenter,
randomized, controlled study to access the safety and efficacy of 700 ug
dexamethasone posterior segment drug delivery system applicator system
as adjunctive therapy to Lucentis 500 ug versus Lucentis alone in the
treatment of patients with choroidal neovascularization secondary to agerelated
macular degeneration. Allergan 206207-016-00.

Principal Investigator, 2008-2009. A phase I, single ascending dose trial to establish
the safety, tolerability and pharmacokinetic profile of intravitreous
injections of E10030 (anti-PDGF pegylated aptamer) monotherapy and
E10030 given in combinations with Lucentis 0.5 mg/eye in subjects with
neovascular age-related macular degeneration. REGRESS, Ophthotech
OPH1000.

Principal Investigator, 2008-ongoing. A double-masked. Randomized, parallel-group
study to investigate the pharmacodynamics, safety, and systemic
pharmacokinetics of pazopanib eye drops, administered for 28 days to
adult subjects with neovascular age-related macular degeneration.
GlaxoSmithKline (GSK) MD7108240.

Principal Investigator, 2008-ongoing. A randomized, double-blind, placebocontrolled
study to evaluate the ocular safety of SCH 530348 in subjects
participating in the Schering-Plough P04737 study (TRA-secondary
prevention ocular safety study. Schering Plough P05183.

Principal Investigator, 2008-ongoing. A Phase 2, Randomized, Double-Masked,
Placebo-Controlled, Dose-Ranging Clinical Study to Assess the Safety and
Efficacy of Subconjunctival Injections of Sirolimus in Patients with
Diabetic Macular Edema Secondary to Diabetic Retinopathy. MacuSight
DR-002, DIAMOND.

Principal Investigator, 2008-ongoing. An extension study to protocol MD7108240;
pazopanib eye drops in subjects with neovascular age-related macular
degeneration. GlaxoSmithKline (GSK) MD7108240 extension.

Principal Investigator, 2008-ongoing. A Double-Blind, Randomized, Placebo-
Controlled, 2-Part Study to Assess the Safety, Tolerability, and Pharmacokinetics
of Single and Multiple Doses of L-000796568 Administered With a Meal in
Young Healthy Male Subjects. Merck & Company 008-00.

Principal Investigator, 2008-ongoing. Pharmacokinetic evaluation of various
controlled-release JNJ-26113100 formulations relative to immediate
release formulation. Alza Corporation C-2006-022-02.

Principal Investigator, 2008-ongoing. A phase 2, randomized, masked, controlled
clinical study to asses the safety and efficacy of Lucentis plus Sirolimus
versus Lucentis plus placebo in patients with sub-foveal choroidal
neovascularization secondary to age-related macular degeneration.
Macusight EMERALD.

Principal Investigator, 2009-ongoing. A multi-center randomized clinical trial to
assess the relative safety and efficacy of Lucentis and Avastin in the
treatment of subfoveal choroidal neovascularization secondary to agerelated
macular degeneration. Sponsored by National Eye Institute.
CATT

Principal Investigator, 2009-ongoing. A randomized, double masked, controlled
phase 3 study of the efficacy, safety, and tolerability of repeated
intravitreal administration of VEGF Trap - Eye in Subjects with macular
edema secondary to central retinal vein occlusion. Regeneron VGFTOD-
0819, COPERNICUS.

Principal Investigator, 2010-ongoing. Ranibizumab for edema of the macula in
diabetes: protocol 3 with high dose - the READ 3 study. This is an
investigator sponsored trial, lead by Quan Nguyen, MD, from Wilmer
Ophthalmological Institute. Sponsored by the Juvenile Diabetes Research
Foundation. READ3. IND 11768

Principal Investigator, 2010-ongoing. A phase 2, randomized, double-masked,
controlled trial to establish the safety and efficacy of intravitreous
injections of 310030 (anti-PDGF pegylated aptamer) given in combination
with Lucentis in subjects with neovascular age-related macular
degeneration. Ophthotech

Principal Investigator, 2010-ongoing. A phase 1/2a, monocular, randomized, fellow
eye-controlled, comparative study of a single subretinal administration of
human umbilical tissue-derived stem cells (CNTO 2476) in subjects with
visual acuity impairment associated with geographic atrophy caused by
age-related macular degeneration. Centocor, a division of
Johnson&Johnson.

Principal Investigator, 2010-ongoing. A phase 1b/2 multi-center, randomized, singlemasked,
sham injection-controlled study of safety, tolerability, and
evidence of activity of FCFD4514S intravitreal injections administered
monthly or every other month to patients with geographic atrophy.
Genentech CFD4870g. MAHALO

Principle Investigator, 2011-ongoing. A double masked, randomized, activecontrolled,
phase 3 study of the efficacy and safety of intravitreal
administration of VEGF trap-eye in subjects with diabetic macular edema.
Regeneron VGFT-OD-1009.

Principle Investigator, 2011-ongoing. A randomized, multi-center, phase 2 study of
the safety, tolerability and bioactivity of repeated intravitreal injections of
iCo-007 as monotherapy or in combination with ranibizumab or laser
photocoagulation in the treatment of diabetic macular edema with
involvement of the foveal center. Juvenile Diabetes Research Foundation
iDEAL.

NATIONAL CLINICAL TRIALS - SUB-INVESTIGATOR
Sub-Investigator, 2002-2007. A Multi-centered, Randomized, Double Masked,
Controlled Study to Evaluate Safety and Efficacy of an Intravitreal
Fluocinolone Acetonide (0.5 or 2 mg) Implant in Non-Infectious Uveitis
Affecting the Posterior Segment of the Eye. Bausch and Lomb.

Sub-Investigator, 2001-2005. A Multi-centered, Randomized, Clinical Trial of
Intravitreal Immusol for the treatment of Proliferative Vitreo-Retinopathy.

Sub-Investigator, 2001-2006. A Multi-centered, Randomized, Phase III Study
Comparing Subtenons Anecortave Acetate to Visudyne Photodynamic
Therapy in Classic Subfoveal Choroidal Neovascularization, from Age-
Related Macular Degeneration. Alcon Pharmaceuticals.

Sub-Investigator, 2003-2006. A Phase III, Multi-centered, Randomized, Double-
Masked, Sham Injection-Controlled Study of the Efficacy and Safety of
rhuFab V2 in Subjects with Minimally Classic or Occult Subfoveal
Neovascular Age-Related Macular Degeneration (MARINA). Genentech.

Sub-Investigator, 2005-ongoing. An open-label multicenter extension study to
evaluate the safety and tolerability of ranibizumab in subjects with
subfoveal choroidal neovascularization secondary to age-related macular
degeneration who have completed the treatment phase of a Genentech
sponsored ranibizumab study (HORIZON). Genentech FVF3426g.

Sub-Investigator, 2006-2007. A Phase IV, open label, multi-center trial of
maintenance intravitreous injections of Macugen every six weeks for 48
weeks in subjects with subfoveal neovascular age-related macular
degeneration initially treated with a modality resulting in maculopathy
improvement.

Sub-Investigator, 2007-2009. A 24-month randomized, double-masked, controlled,
multicenter, phase IIIB study assessing safety and efficacy of verteporfin
(Visudyne) photodynamic therapy administered in conjunction with
ranibizumab (Lucentis) versus ranibizumab monotherapy in patients with
subfoveal choroidal neovascularization secondary to AMD. Novartis,
BPD952A2308, DENALI.

Sub-Investigator, 2006-2007. A phase I, dose-escalation safety study of CGC-11047
in patients with choroidal neovascularization due to AMD. Cellgate 47-
MD-001.

Sub-Investigator. 2007- ongoing A phase III, double-masked, multicenter,
randomized, sham-controlled study of the efficacy and safety of
ranibizumab injection in subjects with clinically significant macular
edema with center involvement secondary to diabetes mellitus. Genentech
FVF 4168g.

Sub-Investigator, 2006-ongoing. A phase III, double-masked, multicenter,
randomized, sham-controlled study of the efficacy and safety of
ranibizumab injection in subjects with clinically significant macular
edema with center involvement secondary to diabetes mellitus. Genentech
FVF4168g RIDE.

Sub-Investigator, 2007-ongoing. A phase III, multicenter, randomized, sham
injection-controlled study of the efficacy and safety of ranibizumab
injection compared with sham in subjects with macular edema secondary
to central retinal vein occlusion. FVF4166g CRUISE.

Sub-Investigator, 2007-ongoing. A phase III, multicenter, randomized, sham
injection-controlled study of the efficacy and safety of ranibizumab
injection compared with sham in subjects with macular edema secondary
to branch retinal vein occlusion. FVF4165g BRAVO.

Sub-Investigator, 2009-ongoing. The safety and efficacy of AL-8309B Ophthalmic
Solution for the treatment of geographic atrophy secondary to age-related
macular degeneration. Alcon AL-8309B225916. GATE

Sub-Investigator, 2009-ongoing. A phase III, multicenter, randomized, doublemasked
study comparing the efficacy and safety of 0.5-mg and 2.0-mg
ranibizumab administered monthly or on an as-needed basis (PRN) with a
safety run-in of a single dose of 2.0-mg ranibizumab with subfoveal
neovascular age-related macular degeneration. Genentech FVF4579g.

Sub-Investigator, 2010-ongoing. Controlled, double-masked, randomized,
multicenter study to evaluate AL-78898A as a treatment for exudative
AMD. Alcon RACE.

Sub-Investigator, 2010-ongoing. A phase 2, randomized, double-masked, controlled
trial to establish the safety and efficacy of intravitreous injections of
E10030 (anti-PDGF pegylated aptamer) given in combination with
Lucentis in subjects with neovascular age-related macular degeneration.
Ophthotech OPH1001.

Sub-Investigator. Intravitreal Ranibizumab vs. Triamcinolone vs. Sham in
Combination with Laser Photocoagulation for Diabetic Macular Edema.
JAEB Health and Research. DRCR I

Sub-Investigator. Intravitreal Ranibizumab vs. Triamcinolone vs. Sham in
combination with Laser Photocoagulation and PRP Laser for PDR. JAEB
Health and Research. DRCR J

Sub-Investigator. TD/SD OCT Comparison and Reproducibility. JAEB Health and
Research. DRCR O.

Sub-Investigator. Pilot study for Laser Photocoagulation for Diabetic Macular
Edema. JAEB Health and Research. DRCR A.

Sub-Investigator. A Randomized trial comparing Intravitreal Triamcinolone
Acetonide and Laser Photocoagulation for Diabetic Macular Edema.
JAEB Health and Research. DRCR B.

Sub-Investigator. A Phase 2 Evaluation of Anti-VEGF Therapy for Diabetic Macular
Edema: Bevacizumab. JAEB Health and Research. DRCR H.

Sub-Investigator. The Course Response to Focal Photocoagulation for Diabetic
Macular Edema. JAEB Health and Research. DRCR K.

Sub-Investigator. Determine if glycemic control in individuals with type I or II
diabetes can be improved with a personalized risk assessment for diabetic
retinopathy and other complications of diabetes during a visit to a retina
specialist. JAEB Health and Research. DRCR M.

Publications
1. Green BS, Halperin LS, DeBari VA, Needle MA: Cation-DNA complexes. Formation of
complexes studied by laser light scattering. Journal Applied Biochem 1981;3:337-343.
2. Halperin LS, Schoch LH: Acute angle closure glaucoma after scleral buckling for
retinopathy of prematurity. Archives of Ophthalmology, 1988;106:453.
3. Halperin LS, Roseman RL: Successful treatment of a subretinal abscess in an intravenous
drug abuser. Archives of Ophthalmology 1988;106:1651-1652.
4. Striph GG, Halperin LS, Stevens JL, Chu FC: Afferent pupillary defects caused by
hyphemas. American Journal of Ophthalmology 1988;106:352-353.
5. Halperin LS, Lewis H, Blumenkranz MS, Gass JDM, Olk RJ, Fine SL: Choroidal
neovascular membrane and other chorioretinal complications of acquired syphilis.
American Journal of Ophthalmology 1989;108:554-562.
6. Halperin LS, Olk RJ, Soubrane G, Coscas G: Safety of fluorescein angiography during
pregnancy. American Journal of Ophthalmology 1990;109:563-566.
7. Thomas MA, Halperin LS: Subretinal endolaser treatment of choroidal bleeding.
American Journal of Ophthalmology, 1990;109:742-744.
8. Halperin LS, Olk RJ, Soubrane G, Coscas G: Response to letter to the editor concerning
"Safety of fluorescein angiography during pregnancy." American Journal of
Ophthalmology 1990;110:324-325.
9. Halperin LS, Berger A, Grand MG: Syphilitic disc edema & periphlebitis. Retina
1990;10:223-225.
10. Halperin LS: Sneezing as an early indicator of allergy to fluorescein dye. American
Journal of Ophthalmology 1991;112:601-602.
11. Halperin LS: Neuroretinitis caused by seronegative syphilis associated with human
immunodeficiency virus. Journal of Clinical Neuro-Ophthalmology 1992; 12: 171-172.
12. Halperin LS, Goldman HB: Cystoid macular edema associated with phospholine iodine.
Annals of Ophthalmology 1993; 25:457-8..
13. Keyser BJ, Maguire JI, Halperin LS: Propionibacterium acnes endophthalmitis after Staph.
epidermidis endophthalmitis. American Journal of Ophthalmology, 1993; 116: 505-506.
14. Halperin LS: A new way to visualize the macula during laser photocoagulation. Retina,
1998; 18 (6): 571.
15.Amirikia A, Scott IU, Murray TG, Halperin LS: Acute bilateral visual loss associated with
retinal hemorrhages following epiduroscopy. Archives Ophthalmology, 2000; 118: 287-9.
16.Shuler MF, Halperin LS, Murray TG: Pseudo-idiopathic central serous choroidopathy and
choroidal infiltration in a leukemic patient. Submitted.
17.Pollack AL, McDonald HR, Ai E, Green WR, Halperin LS, et al.: Sympathetic Ophthalmia
associated with pars plana vitrectomy without antecedent penetrating trauma. Retina,
2001; 21: 146-154.
18.Halperin LS: On the shoulders of giants: The story of the Washington University Dept. of
Ophthalmology and Visual Sciences. Archives Ophthalmol, 2001; 119: 1567-1568.
19.Halperin LS: Beware Retinal Detachment. Eyenet, 2002; October: 8.
20.Fu AD, McDonald HR, Eliot D, Fuller DG, Halperin LS, Ramsay RC, Johnson RN, Ai E:
Complications of general anesthesia using nitrous oxide in eyes with pre-existing gas
bubbles. Retina, 2002; 22: 569-574.
21.Hilton GF, Josephberg RG, Halperin LS, Madreperla SA, et al.: Office-based sutureless
transconjunctival pars plana vitrectomy. Retina, 2002; 22: 725-732.
22.Halperin LS: Discussion of Diagnostic and Therapeutic Challenges. Retina, 2003; 23:
224-229.
23.Halperin LS, Prenner JL: AMD: The tried and true and the truly new. Review of
Ophthalmology, 2006; 13: 54-59.
24.Kleinman M, Pearson A, Halperin LS: Acute rise of intraocular pressure after intravitreal
kenalog due to variable crystal size. Submitted to American Journal of Ophthalmology.
25.Verteporfin Therapy of subfoveal occult with no classic choroidal neovascularization in
age-related macular degeneration: two-year results of a randomized clinical trial.
Submitted. Member of writing committee
26. Klein KS, Walsh MK, Hassan TS, Halperin LS, Castellarin AA, Roth D, Driscoll S,
Prenner JL: Endophthalmitis after anti-vascular endothelial growth injections.
Ophthalmology, 2009; 116: 1225.
27.Zhang K, Hopkins J, Heier J, Birch D, Halperin L, Albini T, Brown D, Jaffe G, Tao W,
Williams G: Phase 2 trial of ciliary neurotrophic factor delivered by encapsulated cell
intraocular implants for treatment of geographic atrophy in age-related macular
degeneration. In preparation.
28.Kleinman ME, Westhouse SJ, Ambati J, Pearson PA, Halperin LS: Triamcinolone crystal
size. Ophthalmology; 2010; 117, 1654.
29.Halperin LS, Hasan T: Acute onset of severe macular pucker associated with severe vision
loss. In preparation.
30.Halperin LS: Durezol vs. Durasal. EyeNet Magazine, October 2011; 15.

Location

6333 North Federal Highway, Suite 300
Fort Lauderdale, FL 33308

Map

My Health Patient Portal